Stäng. Anti-SIRP alpha antibodies as a potential new tool for cancer immunotherapy Furthermore, an anti-SIRP alpha Ab that blocks the interaction with CD47

Anti-CD47/PD-L1 immunotherapies aiming to enhance antitumor immunity are being intensively investigated and show promising results in cancer therapy; however, not all patients treated with these new drugs respond. Thus, developing new immunotherapy agents or combination treatments to enhance the efficacy of immunotherapy is an urgent challenge.

Wiersma VR, van Bommel PE, de Bruyn M, et al. CD47, a multi-facetted target for cancer immunotherapy. Atlas of Genetics and Cytogenetics in Oncology and Haematology website. http 2018-12-11 · Monotherapy by CD47 blockade led to a reduction in tumor growth and an increase in overall survival. Of note, this treatment lead to a moderate depletion of M2 macrophages as well as close-to-complete elimination of regulatory T cells from the tumor bed, suggesting a strong favorable impact of CD47 blockade on the tumor microenvironment. The suppressive effect of macrophages was enhanced by blocking CD47 on pancreatic cancer cells, leading to decreased metastatic burden and prolonged survival. This work supports a clinical trial of CD47 blockade as an adjuvant immunotherapy for pancreatic cancer.

Half of the participants responded positively to the treatment, aimed at triggering macrophages to engulf cancer cells, the researchers reported. 2016-11-15 · The anti-CD47 immunotherapy agent SRF231 has shown early promise as a treatment for a number of cancers, with potent anti-tumor activity, both as a monotherapy and in combination with standard of care therapies, by inducing macrophage-mediated immune responses. Preclinical data on SRF231 was Introduction: CD47 is an anti-phagocytic ('don't eat me') signal overexpressed in many malignant diseases. It acts as myeloid immune checkpoint and thus has prognostic and therapeutic implications. Areas covered : This review presents and discusses the currently available data on the prognostic role and therapeutic value of CD47 in gastrointestinal tumors. The CD47 gene is located on chromosome 3q13 and encodes an integrin-associated protein.

CD47, a ‘marker-of-self’ protein that is overexpressed broadly across tumor types, is emerging as a novel potent macrophage immune checkpoint for cancer immunotherapy. Recently, CD47 blockade by Hu5F9-G4 has shown promise combined with Rituximab in non-Hodgkin’s lymphoma.

The suppressive effect of macrophages was enhanced by blocking CD47 on pancreatic cancer cells, leading to decreased metastatic burden and prolonged survival. This work supports a clinical trial of CD47 blockade as an adjuvant immunotherapy for pancreatic cancer.

Mar 6, 2020 The gut microbiome modulates gut immunity and affects the host response to cancer immunotherapy, but how microbiota influence the tumor

The combination of CD47 blockade and macrophage activation by cabazitaxel synergizes to vastly enhance the elimination of TNBC cells.

Inhibitors of the CD47-SIRPα interaction improve antitumor antibody responses by enhancing antibody-dependent cellular p … 2020-08-01 Introduction: CD47 is an anti-phagocytic ('don't eat me') signal overexpressed in many malignant diseases. It acts as myeloid immune checkpoint and thus has prognostic and therapeutic implications. Areas covered : This review presents and discusses the currently available data on the prognostic role and therapeutic value of CD47 in gastrointestinal tumors. 2017-09-19 As important innate immune cells, macrophages play important roles in maintaining homeostasis, preventing pathogen invasion, resisting tumor cells and promoting adaptive immune response. CD47 is found to be overexpressed on tumor cells and act as a don't eat me' signal, which contributes to immune evasion.
Ekonom lonec merkur

Inhibitors of the CD47-SIRPα interaction improve antitumor antibody responses by enhancing antibody-dependent cellular p … The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy As a transmembrane protein, CD47 plays an important role in mediating cell proliferation, migration, phagocytosis, apoptosis, immune homeostasis, inhibition of NO signal transduction and other related reactions. Immunohistochemistry and flow cytometry were used to measure CD47 ("don't eat me signal") expression on tumor cells and characterize macrophages in the tumor microenvironment. In vitro engulfment assays and mouse experiments were performed with CD47-blocking antibodies to assess macrophage engulfment of tumor cells, progression of micrometastases in the liver and mouse survival.

The treatment of diseases by inducing, enhancing, or surpressing an immune Oct 1, 2018 CD47 has been found to be present on leukemic stem cells, but not on normal Is CD47 a good target for immunotherapy in lymphoma?
Inre vagel

Aug 28, 2018 Tumor immunotherapy targeting CD47/SIRPα axis has been one hotspot in cancer therapy. Here, we summarize the preclinical evidence and

In a study of mice, Casey et al.

However, immunotherapies related to innate responses such as CD47 blockade rely on the rapid immune responses within the tumor microenvironment. Using one defined anaerobic gut microbiota to track whether microbiota interact with host immunity, we observed that Bifidobacterium facilitates local anti-CD47 immunotherapy on tumor tissues through the capacity to accumulate within the tumor microenvironment.

Introduction: CD47 is an anti-phagocytic ('don't eat me') signal overexpressed in many malignant diseases.

Thus, developing new immunotherapy agents or combination treatments to enhance the efficacy of immunotherapy is an urgent challenge.